Brief: Precigen Commercial Readiness Preparations Are Underway For A Potential US Launch In 2025

Precigen

16/01/2024 13:08

Jan 16 (Reuters) - Precigen Inc  PGEN.O :
    * PRECIGEN RECEIVES ORPHAN DRUG DESIGNATION FOR PRGN-2012
FOR THE
TREATMENT OF RECURRENT RESPIRATORY PAPILLOMATOSIS FROM THE
EUROPEAN COMMISSION
    * PRECIGEN INC - COMMERCIAL READINESS PREPARATIONS ARE
UNDERWAY
FOR A POTENTIAL LAUNCH IN UNITED STATES IN 2025
    * PRECIGEN INC - PRGN-2012 IS CURRENTLY UNDER INVESTIGATION
IN A
PHASE 1/2 PIVOTAL SINGLE-ARM STUDY IN ADULT PATIENTS WITH RRP IN
UNITED STATES

Source text for Eikon:  ID:nPn3fJ1qra 
Further company coverage:  PGEN.O 

 ((Reuters.Briefs@thomsonreuters.com;))